Jess S. Morgan & Co’s Oramed Pharmaceuticals ORMP Stock Holding History

Jess S. Morgan & Co’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.37M	Buy	366,401 +51,100	+16%	+$414K	2.07%	25
2022 Q2	$1.44M	Buy	315,301 +24,800	+9%	+$133K	1.5%	25
2022 Q1	$2.51M	Buy	290,501 +75,100	+35%	+$769K	1.83%	30
2021 Q4	$3.08M	Buy	215,401 +1,500	+0.7%	+$31.4K	1.89%	31
2021 Q3	$4.7M	Sell	213,901 -108,348	-34%	-$1.85M	3.1%	6
2021 Q2	$4.31M	Sell	322,249 -57,695	-15%	-$660K	2.83%	16
2021 Q1	$3.86M	Sell	379,944 -197,373	-34%	-$1.62M	2.7%	14
2020 Q4	$2.45M	Buy	577,317 +1,000	+0.2%	+$3.25K	1.95%	31
2020 Q3	$1.5M	Buy	576,317 +163,424	+40%	+$569K	1.5%	35
2020 Q2	$1.46M	Buy	412,893 +380,993	+1,194%	+$1.28M	1.58%	34
2020 Q1	$97K	Buy	31,900 +1,000	+3%	+$4.38K	0.13%	35
2019 Q4	$159K	Buy	+30,900	New	+$116K	0.16%	39

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Jess S. Morgan & Co's ORMP Position: Q3 2022 in Review

Jess S. Morgan & Co increased its Oramed Pharmaceuticals (ORMP) stake by 16% in Q3 2022, buying an estimated $414K and bringing the position to 366,401 shares worth $2.37M. The position accounts for 2.07% of the portfolio, ranked #25.

Jess S. Morgan & Co first reported a position in ORMP in Q4 2019 and has held it in 12 quarters since. The position peaked at $4.7M in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

Jess S. Morgan & Co held 366,401 shares of Oramed Pharmaceuticals worth $2.37M as of Q3 2022.
Jess S. Morgan & Co bought 51,100 Oramed Pharmaceuticals shares in Q3 2022, an estimated $414K.
Oramed Pharmaceuticals made up 2.07% of Jess S. Morgan & Co's portfolio in Q3 2022, its #25 holding.
Jess S. Morgan & Co first reported a position in Oramed Pharmaceuticals in Q4 2019 and has held it in 12 quarters since.
Jess S. Morgan & Co's Oramed Pharmaceuticals position peaked at $4.7M in Q3 2021.
71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Jess S. Morgan & Co's 13F filing for Q3 2022, filed 21 Oct 2022.